Mechanisms of systemic inflammation associated with intestinal injury

Inflammatory Bowel Disease: From Bench to Bedside

Volumn , Issue , 2006, Pages 305-335

  Sartor, R Balfour ^a   Lichtman, Steven N ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891390227     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-25808-6_16     Document Type: Chapter

References (287)

1. Kal JP, Lichtenslcin GR. Rhcumalologic manifestations of gastrointestinal diseases. Gastroenterol Clin N Am 1998; 27: 533-62
2. Leino R, Toivanen A. Arthritis associated with gastrointestinal disorders. In: Toivanen A, Toivanen R eds. Reactive Arthritis. Boca Raton: CRC Press, 1988: 000
3. Jorizzo JL, Apisarnthanarax P, Subrt P et al. Bowel-bypass syndrome without bowel bypass. Arch Intern Med 1983; 143:457-61
4. Greenstein AJ, Janowitz HD, Sachar DB. The extraintestinal complications of crohn's disease and ulcerative colitis: A study of 700 patients. Medicine 1976; 55: 401-12
5. Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative crohn's Disease Study: Extraintestinal manifestation and perianal complications. Gastroenterology 1979;77:914-20
6. Monsen U, Sorstad J, Hellers G, Johansson C. Extracolonic diagnoses in ulcerative colitis: An epidemiological study. Am J Gastroenterol. 1990; 85: 711-16
7. Jacobsen MB, Fausa O, Elgio K, Schrumpf E. Hepatic lesions in adult coeliac disease. Scand J Gastroenterol. 1990;25:656-62
8. Bourne JT, Kumar P, Huskisson EC, Mageed R, Unsworth IJ, Wojtulewski JA. Arthritis and celiac disease. Ann Rheum Dis 1985;44:592-8
9. Klein S, Mayer L, Present DH, Youner KD, Cerulli MA, Sachar DB. Extraintestinal manifestations in patients with diverticulitis. Ann Intern Med 1988; 108: 700-2
10. Toivanen A, Toivanen P. Reactive arthritis. Curr Opin Rheumatol 2000; 12:300-5
11. Bocanegra TS, Espinoza LR, Bridgeford PH, Vasey FB, Germain BE. Reactive arthritis induced by parasitic infestation. Ann Intern Med 1981; 94: 207-9
12. Lichtman SN, Sartor RB, Keku J, Schwab JH. Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 1990; 98: 414-23
13. Lichtman SN, Wang J, Sartor RB et al. Reactivation of arthritis induced by small bowel bacterial overgrowth in rats: Role of cytokines, bacteria, and bacterial polymers. Infect Immun 1995; 63: 2295-301
14. Schultz M, Tonkonogy SL, Sellon RK et al. IL-2-Deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol 1999; 276: G1461-72
15. Sartor RB, Bender DE, Holt LC. Susceptibility of inbred rat strains to intestinal and extraintestinal inflammation induced by indomethacin. Gastroenterology 1992; 102: A690 (abstract
16. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/offregulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-Associated immunopathologies. Immunity 1999; 10: 387-98
17. Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A. Primary sclerosing cholangitis: A long-Term follow-up study. Scand J Gastroenterol 1987; 22: 655-64
18. De Vos M, Cuvelier C, Mielants H, Veys E, Barbier F, Elewaut A. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology 1989; 96: 339-44
19. Rabinovitz M, Gavaler JS, Schade RR, Dindzans VJ, Chien MC, Van Thiel DH. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology 1990; 11: 7-11
20. Suh CH, Lee CH, Lee c et al. Arthritic manifestations of inflammatory bowel disease. J Korean Med Sci 1998; 13: 39-43
21. Buskila D, Odes LR, Neumann L, Odes HS. Fibromyalgia in inflammatory bowel disease. J Rheumatol 1999; 26: 1167-171
22. Wright V, Watkinson G. The arthritis of ulcerative colitis. Medicine 1959; 38: 243-59
23. Olsson R, Danielsson A, Jarnerot G. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 1319-23
24. Bardazzi G, Mannoni A, d'Albasio G et al. Spondylarthritis in patients with ulcerative colitis. Italian J Gastroenterol Hepatol 1997; 29: 520-4
25. Eastwood CJ Epidemic reactive arthritis. Ann Rheum Dis 1990; 49: 73-4
26. Hermon-Taylor J, Bull TJ, Sheridan JM, Cheng J, Stellakis ML, Sumar N. Causation of crohn's disease by Mycobacterium avium subspecies paratuberculosis. Can J Gastroenterol 2000; 14:521-39
27. Wakefield AJ, Montgomery SM, Pounder RE. crohn's disease: The case for measles virus. Ital J Gastroenterol Hepatol 1999;31:247-54
28. Ambrose NS, Johnson M, Burdon DW, Keighley MR. Incidence of pathogenic bacteria from mesenteric lymph nodes and ileal serosa during crohn's disease surgery. Br J Surg 1984;71: 623-5
29. Brooke BN, Dykes PW, Walker EC. A study of liver disorder in ulcerative colitis. Postgrad Med J 1961; 37: 245-51
30. Vinnik IE, Kern F, Struthers JE, Hill RB, Guzak S. Experimental chronic portal vein bacteremia. Proc Soc Exp Biol Med 1964; 15:311-14
31. Olsson R, Bjornsson E, Backman L et al. Bile duct bacterial isolates in primary sclerosing cholangitis: A study of explanted livers. J Hepatol 1998; 28: 426-32
32. Cox KL, Coc KM. Oral vancomycin treatment of PSC in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998; 27: 580-3
33. Nilsson HO, Taneera J, Castedal M, Glatz E, Olsson R, Wadstrom T. Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. J Clin Microbiol 2000; 38: 1072-6
34. Pearce CB, Duncan HD, Timmis L, Green Jr. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 439-43
35. Foltz CJ, Fox JG, Cahill R et al Spontaneous inflammatory bowel disease in multiple mutant mouse Unes: Association with colonization by Helicobacter hepaticus. Helicobacter 1998; 3: 69-78
36. Nilsson I, Lindgren S, Eriksson S, Wadstrom T. Serum antibodies to Helicobacter hepaticus and Helicobacter pylori in patients with chronic liver disease. Gut 2000; 46: 410-14
37. Sherlock S. Pathogenesis of sclerosing cholangitis: The role of nonimmune factors. Semin Liver Dis 1991; 11: 5-10
38. Cello JP. Acquired immunodeficiency syndrome cholangiopathy: Spectrum of disease. Am J Med 1989; 86: 539-46
39. Chen XM, Levine SA, Tietz P et al. Cryptosporidiumparvum is cytopathic for cultured human biliary epithelia via an apoptotic mechanism. Hepatology 1998; 28: 906-13
40. Narayanan Menon KV, Esner RH. Etiology and natural history of primary sclerosing cholangitis. J Hepato-Biliary-Pancreat Surg 1999; 6: 343-51
41. Raj V, Lichtenstein DR. Hepatobiliary manifestations of inflammatory bowel disease. Gastroenterol Clin N Am 1999;28:491-513
42. LaRusso NF. The Fifth Carlos E. Rubio Memorial Lecture. Sclerosing cholangitis: Pathogenesis, pathology, and practice. PR Health Sci J 1999; 18: 11-17
43. Granfors K, Jalkanen S, Essen RV. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med 1989; 320: 216-21
44. Wordsworth BP, Hughes RA, Allan L, Keat AC, Bell JL Chlamydial DNA is absent from joints of patients with sexually acquired reactive arthritis. Br J Rheumatol 1990; 29: 208-10
45. Thiel A, Wu P, Lauster R, Braun J, Radbruch A, Sieper J Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Arthritis Rheum 2000; 43: 2834-42
46. Yu DT. Pathogenesis of reactive arthritis. Intern Med 1999; 38:97-101
47. Wuorela M, Jal, Toivanen P, Granfors K. Intracellular pathogens and professional phagocytes in reactive arthritis. Pathobiology 1991; 59: 162-5
48. Rynes RI, Volastro PS, Bartholomew LE. Exacerbation of B27 positive spondyloarthropathy by enteric infections. J Rheumatol 1984; 11:96-7
49. Wakefield D, McCluskey P, Verma M, Aziz K, Gatus B, Carr G. Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis. Arthritis Rheum 1999; 42: 1894-7
50. Hill JL, Yu DTY Development of an experimental animal model for reactive arthritis induced by Yersinia enterocolitica infection. Infect Immun 1987; 55: 721-6
51. de los Toyos JR, Vazquez J, Sampedro A, Hardisson C. Yersinia enterocolitica serotype 0: 3 is arthritogenic for mice. Microb Pathogen 1990; 8: 370
52. Volkman A, Collins FM. Pathogenesis of Salmonella-Associated arthritis in rats. Infect Immun 1975; 11: 222-30
53. Hermann E, Mayet WJ, Poralla T, Meyer Zum Buschenfelde KH. Salmonella-TQactivQ synovial fluid T cell clones in a patient with post-infectious Salmonella arthritis. Scand J Rheumatol 1990; 19: 350-5
54. Taurog JD, Richardson JA, Croft JT et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 2359-64
55. Rath HC, Herfarth HH, Ikeda JS et al.Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobuHn transgenic rats. J Clin Invest 1996; 98: 945-53
56. Driessen LHHM, van Saene HKF. A novel treatment of pyoderma gangrenosum by intestinal decontamination. Br J Dermatol 1983; 108: 108 (abstract
57. Johnson LA, Wirostko E, Wirostko W. Parasitization of vitreous leukocytes by moUiculte-like organisms. Am J Clin Pathol 1989; 91: 259-64
58. Wakefield D, Stahlberg TH, Toivanen A, Granfors K, Tennant C. Serologic evidence of Yersinia infection in patients with anterior uveitis. Arch Ophthalmol 1990; 108: 219-21
59. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997;92:5S-11S.
60. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998; 115: 182-205
61. Saarinen S, Olerup O, Broom U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 3195-9
62. Kofiier D, Minkowitz MD, Rothman W, Garlock J Immunocytochemical studies in ulcerative colitis and regional ileitis. J Exp Med 1962; 41: 733-1
63. Chapman RW, Cottone M, Selby WS, Shepherd HA, Sherlock S, Jewell DP. Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis. Gut 1986; 27: 86-91
64. Snook JA, Chapman RW, Fleming K, Jewell DP. Antineutrophil nuclear antibody in ulcerative colitis, crohn's disease and primary sclerosing cholangitis. Clin Exp Immunol 1989; 76: 30-3
65. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990; 86: 202-10
66. Roozendaal C, Kallenberg CG Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? CHn Exp Immunol 1999; 116: 206-13
67. Duerr RH, Targan SR, Landers CJ Neutrophil cytoplasmic antibodies: A link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991; 100: 1385-91
68. Lindgren S, Nilsson S, Nassberger L, Verbaan H, Wieslander J Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: Prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK). J Gastroenterol Hepatol 2000; 15: 437-42
69. Orth T, Neurath M, Schirmacher P, Treichel U, Meyer Zum Buschenfelde KH, Mayet W. Anti-neutrophil cytoplasmic antibodies in a rat model of TNBS acid-induced liver injury. Eur J Clin Invest 1999; 29: 929-39
70. Roozendaal C, van Milligen de Wit AW, Haagsma EB et al. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: Defined specificities may be associated with distinct clinical features. Am J Med 1998; 105: 393-9
71. Orth T, Kellner R, Diekmann O, Faust J, Meyer Zum Buschenfelde BK, Mayet WJ Identification and characterization of autoantibodies against catalase and alpha-enolase in patients with primary sclerosing cholangitis. Clin Exp Immunol 1998; 112:507-15
72. Cohavy O, Bruckner D, Gordon LK et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000; 68: 1542-8
73. Eggena M, Cohavy O, Parseghian MH et al. Identification of histone HI as a cognate antigen of the ulcerative colitisassociated marker antibody pANCA. J Autoimmun 2000; 14: 83-97
74. Terjung B, Spengler U, Sauerbruch T, Worman HJ. Atypical p-ANCA' in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119: 310-22
75. Mieli-Vergani G, Lobo-Yeo A, McFarlane BM, McFarlane IG, Mowat AP, Vergani D. Different immune mechanisms leading to autoimmunity in primary sclerosing cholangitis and autoimmune chronic active hepatitis of childhood. Hepatology 1989; 9: 198-203
76. McFarlane IG, Joycicka BM, Tsantoulas DC. Leukocyte migration inhibition in response to biliary antigens in primary biliary cirrhosis, sclerosing cholangitis and other chronic liver diseases. Gastroenterology 1979; 76: 1333-40
77. Angulo P, Peter JB, Gershwin ME et al Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000; 32: 182-7
78. Das KM, Vecchi M, Sakamaki S. A shared and unique cpitope(s) on human colon, skin and biliary epithelium detected by a monoclonal antibody. Gastroenterology 1990:98:464-9
79. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology 1994; 107: 103-8
80. Gcng X, Biancone L, Dai HH et al. Tropomyosin isoforms in intestinal mucosa: Production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology 1998; 114:912-22
81. Mandal A, Dasgupta A, Jeffcrs L et al. Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium. Gastroenterology 1994; 106: 185-92
82. Takahashi F, Das KM. Isolation and characterization of a colonic autoantigen specifically recognized by colon tissuebound immunoglobulin G from idiopathic ulcerative colitis. Clin Invest 1985; 76: 311-18
83. Sakamaki S, Takayanagi N, Yoshizaki N et al. Autoantibodies against the specific epitope of human tropomyosin(s) detected by a peptide based enzyme immunoassay in sera of patients with ulcerative colitis show antibody dependent cell mediated cytotoxicity against HLA-DPw9 transfected L cells. Gut 2000; 47: 236-41
84. Biancone L, Monteleone G, Marasco R, Pallone F. Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives. Clin Exp Immunol 1998; 113: 198-205
85. Ohman L, Franzen L, Rudolph U, Harriman GR, Hultgren HE. Immune activation in the intestinal mucosa before the onset of colitis in Galphai2-Deficient mice. Scand J Immunol 2000; 52: 80-90
86. Mizoguchi A, Mizoguchi E, Chiba C et al. Cytokine imbalance and autoantibody production in T cell receptoralpha mutant mice with inflammatory bowel disease. J Exp Med 1996; 183:847-56
87. Khoo UY, Bjarnason I, Donaghy A, Williams R, Macpherson A. Antibodies to colonic epithelial cells from the serum and colonic mucosal washings in ulcerative colitis. Gut 1995;37:63-70
88. Ueno Y, Phillips JO, Ludwig J, Lichtman SN, LaRusso NF. Development and characterization of a rodent model of immune-mediated cholangitis. Proc Natl Acad Sci USA 1996;93:216-20
89. Ueno Y, Ishii M, Takahashi S, Igarashi T, Toyota T, LaRusso NF. Different susceptibility of mice to immunemediated cholangitis induced by immunization with carbonic anhydrase. Lab Invest 1998; 78: 629-37
90. Gordon SC, Quattrociocchi-Longe TM, Khan BA et al. Antibodies to carbonic anhydrase in patients with immune cholangiopathies. Gastroenterology 1995; 108: 1802-9
91. Broome U, Grunewald J, Scheynius A, Olerup O, Hultcrantz R. Preferential V beta3 usage by hepatic T lymphocytes in patients with primary sclerosing cholangitis. J Hepatol 1997; 26: 527-34
92. Alpini G, Galsser SS, Ueno Y et al. Heterogenicity of the proliferative capacity of rat cholangiocytes after bile duct ligation. Am J Physiol 1998; 274: G767-75
93. Nonomura A, Kono N, Minato H, Nakanuma Y Diffuse biliary tract involvement mimicking primary sclerosing cholangitis in an experimental model of chronic graftversus-host disease in mice. Pathol Int 1998; 48: 421-7
94. Howell CD, Yodre T, Claman HN, Vierling JM. Hepatic homing of mononuclear cells isolated during murine chronic graft-vs-host disease. J Immunol 1989; 143: 476-83
95. Ueno Y, Ishii M, Yahagi K et al. Fas-mediated cholangiopathy in the murine model of graft versus host disease. Hepatology 2000; 31: 966-74
96. Shalaby MR, Fendly B, Sheehan KC Schreiber RD, Ammann AJ Prevention of the graft-vs-host reaction in newborn mice by antibodies to tumor necrosis factor-Alpha. Transplantation 1989; 47: 1057-61
97. Van Der Brink MRM, Moore E, Horndasch KJ et al. Fasdeficient Ipr mice are more susceptible to graft-vs-host disease. J Immunol 2000; 164: 469-80
98. Dienes HP, Lohsc AW, Gerken G et al. Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis. Virchows Archiv 1997; 431: 119-24
99. Yu DTY, Choo SY, Schaack T. Molecular mimicry in HLAB27 related arthritis. Ann Intern Med 1989; 111: 581-91
100. Lopez-Larrea C, Gonzalez S, Martinez-Borra J The role of HLA-B27 polymorphism and molecular mimicry in spondyloarthropathy. Mol Med Today 1998; 4: 540-9
101. Chou CT, Uksila J, Toivanen P. Enterobacterial antibodies in Chinese patients with rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 1998; 16: 161-4
102. Tsuchiya N, Husby G, Williams RC, Sticglitz H, Lipsky PE, Inman RD. Autoantibodies to the HLA B27 sequence crossreact with the hypothetical peptide from the arthritis associated Shigella plasmid. J Clin Invest 1990; 86: 1193-203
103. Tsuchiya N, Husby G, Williams RC. Antibodies to the peptide from the plasmid coded Yersinia outer membrane protein (YOPI) in patients with ankylosing spondylitis. Clin Exp Immunol 1990; 82: 493-8
104. Zhou M, Sayad A, Simmons WA et al. The specificity of peptides bound to human histocompatibility leukocyte antigen (HLA)-B27 influences the prevalence of arthritis in HLA-B27 transgenic rats. J Exp Med 1998; 188: 877-86
105. Khare SD, Bull MJ, Hanson J, Luthra HS, David CS. Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: A direct role for B27 heavy chains and not B27-Derived peptides. J Immunol 1998; 160: 101-6
106. Khare SD, Lee S, Bull MJ et al. Peptide binding alpha 1 alpha2 domain of HLA-B27 contributes to the disease pathogenesis in transgenic mice. Hum Immunol 1999; 60: 116-26
107. Breban M, Hammer RE, Richardson JA, Taurog JD. Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J Exp Med 1993; 178:1607-16
108. Hermann E, Lohse AW, Van Der Zee R. Synovial fluidderived Yersinia reactive T cells responding to human 65 kDa heat shock protein and heat stressed antigen presenting cells. Eur J Immunol 1991; 21: 2139-43
109. Kaufmann SH. Heat shock proteins and the immune response. Immunol Today 1990; 11: 129-36
110. Winrow VR, Mojdehi GM, Ryder SD, Rhodes JM, Blake DR, Rampton DS. Stress proteins in coloreet al mucosa. Enhanced expression in ulcerative colitis. Dig Dis Sci 1993; 38: 1994-2000
111. Baca-Estrada ME, Gupta RS, Stead RH, Croitoru K. Intestinal expression and cellular immune responses to human heat-shock protein 60 in crohn's disease. Dig Dis Sci 1994; 39: 498-506
112. Van Den Broek MF, Hogervorst EJ, van Bruggen MC, Van Eden W, Van Der Zee R, Van Den Berg WB. Protection against streptococcal cell wall-induced arthritis by pretreatment with the 65-kD mycobacterial heat shock protein. J Exp Med 1989; 170:449-66
113. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification of self peptides bound to purified HLAB27. Nature 1991; 353: 326-9
114. Steinhoff U, Brinkmann V, Klemm U et al. Autoimmune intestinal pathology induced by hsp60-specific CD8 T cells. Immunity 1999; 11: 349-58
115. Mertz AK, Wu P, Sturniolo T et al. Multispecific CD4+ T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in Yersinia-inggQXtd reactive arthritis: Overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles. J Immunol 2000; 164: 1529-37
116. Giant XT, Mikecz K. Antiproteoglycan antibodies in experimental spondyloarthritis. In: Kresina TF, ed. Monoclonal Antibodies, Cytokines, and Arthritis. New York: Marcel Dekker, 1991
117. Van Den Broek MF, Van De Putte LB, Van Den Berg WB. crohn's disease associated with arthritis: A possible role for crossreactivity between gut bacteria and cartilage in the pathogenesis of arthritis. Arthritis Rheum 1988; 31: 1077-9
118. Broberger O, Perlmann P. Autoantibodies in human ulcerative colitis. J Exp Med 1959; 110: 657-74
119. Labeille B, Gineston JL, Denoeux JP, Capron JP. Epidermolysis bullosa acquisita and crohn's disease. Arch Intern Med 1988; 148: 1457-9
120. Gordon LK, Eggena M, Holland GN, Weisz JM, Braun J pANCA antibodies in patients with anterior uveitis: Identification of a marker antibody usually associated with ulcerative colitis. J Clin Immunol 1998; 18: 264-71
121. Singh VL, Donoso LA, Yamaki K, Shinohara T. Uveitopathogenic sites in bovines antigen. Autoimmunity 1989; 3: 177-87
122. Li Q, Sun B, Dastgheib K, Chan CC. Suppressive effect of transforming growth factor bet al on the recurrence of experimental melanin protein-induced uveitis: Upregulation of ocular interleukin-10. Clin Immunol Immunopathol 1996;81:55-61
123. Becker MD, Adamus G, Davey MP, Rosenbaum JT. The role of T cells in autoimmune uveitis. Ocular Immunol Inflamm 2000; 8: 93-100
124. Altman AR, Maltz C, Janowitz HD Autoimmune hemolytic anemia in ulcerative colitis. Dig Dis Sci 1979; 24: 282-5
125. Stevens C, Peppercorn MA, Janowitz HD. crohn's disease associated with autoimmune neutropenia. J Clin Gastroenterol 1991; 13:328-30
126. Soltis RD, Hasz D, Morris MJ, Wilson ID. Evidence against the presence of circulating immune complexes in chronic inflammatory bowel disease. Gastroenterology 1979; 76: 1380-5
127. Lawley TJ, James SP, Jones EA. Circulating immune complexes: Their detection and potential significance in some hepatobiliary and intestinal diseases. Gastroenterology 1980;76:626-41
128. Hodgson HJ, Potter BJ, Jewell DP. Immune complexes in ulcerative colitis and crohn's disease. Clin Exp Immunol 1977; 29: 187-96
129. Lake AM, Stitzel AE, Urmson JR, Walker WA, Spitzer RE. Complement alterations in inflammatory bowel disease. Gastroenterology 1979; 76: 1374-9
130. Bodenheimer HC, LaRusso NF, Thayer WR, Charland C, Staples PJ, Ludwig J Elevated circulating immune complexes in primary sclerosing cholangitis. Hepatology 1983; 3: 150-4
131. Alberti-Flor JJ, Medina M, Jeffeers L, SchiffER. Elevated immunoglobulins and immune complexes in the bile of patients with primary sclerosing cholangitis. Hepatology 1983; 3: 844 (abstract
132. Senaldi G, Donaldson PT, Magrin S et al. Activation of the complement system in primary sclerosing cholangitis. Gastroenterology 1989; 97: 1430-4
133. Minuk GY, Angus M, Brickman CM et al. Abnormal clearance of immune complexes from the circulation of patients with primary sclerosing cholangitis. Gastroenterology 1985; 88: 166-70
134. Wands JR, LaMont JT, Mann E, Isselbacher KJ Arthritis associated with intestinal bypass procedure for morbid obesity. N Engl J Med 1976; 294: 121-4
135. Utsinger PD. Systemic immune complex disease following intestinal bypass surgery: Bypass disease. J Am Dermatol 1980; 2: 488-95
136. Zapanta M, Aldo-Benson M, Madura J Clinical and immunological features in patients with postintestinal bypass arthritis. Arthritis Rheum 1978; 21: 599 (abstract
137. Lahesmaa-Rantala R, Granfors K, Isomaki H, Toivanen A. Yersinia specific immune complexes in the synovial fluid of patients with Yersinia triggered reactive arthritis. Ann Rheum Dis 1987;46:510-14
138. Peeters AJ, Warmold A, Van Den Wall Bake L, Van Albada-Kuipers GA. IgA containing immune complexes and hematuria in ankylosing spondylitis. A prospective longitudinal study. J Rheumatol 1988; 15: 1662-7
139. Peeters AJ, Van Den Wall Bake AWL, Daha MR, Breedveld EC. Inflammatory bowel disease and ankylosing spondylitis associated with cutaneous vasculitis, glomerulonephritis, and circulating IgA immune complexes. Ann Rheum Dis 1990; 49: 638-40
140. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety. Inflam Bowel Dis 1999; 5: 119-33
141. Mayer L, Meyers S, Janowitz HD. Cryoproteinemia in the cutaneous gangrene of crohn's disease: A report of two cases. J Clin Gastroenterol 1981; 3: 17-21
142. Stein HB, Otto LA, Schlappner WB, Gourlay RH, Reeve CE. The intestinal bypass arthritis dermatitis syndrome. Arthritis Rheum 1981; 24: 684-90
143. Shum DT, Guenther L. Metastatic crohn's disease. Arch Dermatol 1990; 126: 6455-8
144. Wakefield AJ, Sankey EA, Dhillon AP, Sawyer AFM. Granulomatous vasculitis in crohn's disease. Gastroenterology 1991; 100: 1279-87
145. de Kozak Y. Antibody response in uveitis. Eye 1997; 11: 194-9
146. Sartor RB. Microbial factors in the pathogenesis of crohn's disease, ulcerative colitis and experimental intestinal inflammation. In: Kirsner JB, ed. Inflammatory Bowel Diseases: 5th edition. Philadelphia: WB. Saunders, 1999: 153-78
147. Sartor RB. Intestinal microflora in human and experimental inflammatory bowel disease. Curr Opin Gastroenterol 2001; 17 (In press
148. Sartor RB, Veltkamp C. Interactions between enteric bacteria and the immune system which determine mucosal homeostasis vs chronic intestinal inflammation: Lessons from rodent models. In: Rogler G, Kullmann F, Rutgeerts P, Sartor RB, Scholmerich J, eds. IBD at the End of Its First Century. Dordrecht: Kluwer Academic Publishers, 2000: 30-41
149. Katz KD, Hollander D, Vanheim CM. Intestinal permeability in patients with crohn's disease and their healthy relatives. Gastroenterology 1989; 97: 927-31
150. Wellmann W, Fink PC, Benner F, Schmidt FW. Endotoxaemia in active crohn's disease. Treatment with whole gut irrigation and 5-Aminosalicylic acid. Gut 1986; 27: 814-20
151. Kruis W, Schussler P, Weinzierl M, Galanos C, Eisenburg J Circulating lipid A antibodies despite absence of systemic endotoxemia in patients with crohn's disease. Dig Dis Sci 1984;29: 502-7
152. Anderson RP, Friend GM, Ferry DM, Chadwick VS. Formyl peptidemia in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gastroenterology 1991; 100: A557 (abstract
153. Hobson CH, Butt TJ, Ferry DM, Hunter J, Chadwick VS, Broom MF. Enterohepatic circulation of bacterial chemotactic peptide in rats with experimental colitis. Gastroenterology 1988;94: 1006-13
154. Anderson RP, Butt TJ, Chadwick VS. Hepatobiliary excretion of bacterial formyl-methionyl peptides in rat. Structure activity studies. Dig Dis Sci 1992; 37: 248-56
155. Sartor RB, Bond TM, Schwab JH. Systemic uptake and intestinal inflammatory effects of luminal bacterial cell wall polymers in rats with acute colonic injury. Infect Immun 1988:56:2101-8
156. Vcltkamp C, Tonkonogy SL, Yong Y et al. Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in TG epsilon 26 mice after bone marrow transplantation or adoptive transfer. Gastroenterology 2001; 120: 913
157. Yamada T, Sartor RB, Marshall S, Specian RD, Grisham MB. Mucosal injury and inflammation in a model of chronic granulomatous colitis in rats. Gastroenterology 1993; 104: 759-71
158. Sartor RB, DcLa Cadena RA, Green KD et al. Selective kallikrein kinin system activation in inbred rats differentially susceptible to granulomatous enterocolitis. Gastroenterology 1996; 110: 1467-81
159. Anton PA, Targan SR, Shanahan F. Increased neutrophil receptors for and response to the proinflammatory bacterial peptide formyl-methionyl-lcucyl- phenylalanine in crohn's disease. Gastroenterology 1989; 97: 20-8
160. Stimpson SA, Esser RE, Carter PB, Sartor RB, Cromartie, WJ, Schwab JH. Lipopolysaccharide induces recurrence of arthritis in rat joints previously injured by peptidoglycanpolysaccharide. J Exp Med 1987; 165: 1688-702
161. Kono K, Kunihiko O, Masao O. Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia co/i in rabbits. Gastroenterology 1990;98:414-23
162. Buttery LD, Evans TJ, Springall DR, Carpenter A, Cohen J, Polak JM. Immunochemical localization of inducible nitric oxide synthase in endotoxin-Treated rats. Lab Invest 1994; 71:755-64
163. Park J, Gores GJ, Patel T. Lipopolysaccharide induces cholangiocyte proliferation via an interleukin-6-mediated activation of p44/p42 mitogen-Activated protein kinase. Hepatology 1999; 29: 1037-3
164. Yamada S, Ishii M, Kisara N, Nagatomi R, Toyota T. Macrophages are essential for lymphocyte infiltration in formyl peptide-induced cholangitis in liver. Liver 1999; 19: 253-8
165. Lichtman SN, Keku J, Clark RL, Schwab JH, Sartor RB. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 1991; 13: 766-72
166. Lichtman SN, Keku J, Schwab JH, Sartor RB. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology 1991; 100: 513-19
167. Lichtman SN, Keku J, Schwab JH, Sartor RB. Evidence for peptidoglycan absorption in rats with experimental small bowel bacterial overgrowth. Infect Immun 1991; 59: 555-62
168. Lichtman SN, Sartor RB, Schwab JH. Elimination of peptidoglycan polysaccharide in rat bile. Gastroenterology 1988; 94: 262A (abstract
169. Lichtman SN, Okoruwa EE, Keku J, Schwab JH, Sartor RB. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest 1992; 90: 1313-22
170. Wahl SM, Allen JB, Dougherty S. T lymphocyte dependent evolution of bacterial cell wall induced hepatic granulomas. J Immunol 1986; 137: 2199-209
171. Manthey CL, Kossmann T, Allen JB, Corcoran ML, Brandes ME, Wahl SM. Role of Kupffer cells in developing streptococcal cell wall granulomas. Am J Pathol 1992; 140: 1205-14
172. Sasatomi K, Noguchi K, Sakisaka S, Sata M, Tanikawa K. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1998; 29: 409-16
173. Lichtman SN, Bharucha A, Jorgensen R, Lindor KD. Evidence that the bacterial cell wall polymer, peptidoglycan-polysaccharide, plays a role in primary sclerosing cholangitis. Gastroenterology 1998; 114: A1290 (abstract
174. Gardiner KR, Halliday MI, Barclay GR et al. Significance of systemic cndotoxaemia in inflammatory bowel disease. Gut 1995; 36: 897-901
175. Ely PH. The bowel bypass syndrome: A response to bacterial peptidoglycans. J Am Acad Dermatol 1980; 2: 473-87
176. Park H, Schumacher HR, Zcigler AR. Antibodies to peptidoglycan in patients with spondyloarthritis: A clue to disease etiology? Ann Rheum Dis 1984; 43: 725-8
177. Rahman MU, Ahmed S, Schumacher R, Zeigler AR. High levels of antipeptidoglycan antibodies psoriatic and other seronegative arthritides. J Rheumatol 1990; 17: 621-5
178. Onderdonk AB, Richardson JA, Hammer RE, Taurog JD. Correlation of cecal microflora of HLA-B27 transgenic rats with inflammatory bowel disease. Infect Immun 1998; 66: 6022-3
179. Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bactcroidcs vulgatus and Escherichia coli. Infect Immun 1999; 67: 2969-74
180. Khare SD, Luthra HS, David CS. Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking beta 2-microglobulin: A model of human spondyloarthropathies. J Exp Med 1995; 182: 1153-8
181. Stimpson SA, Schwab JH. Chronic remittent erosive arthritis induced by bacterial peptidoglycan polysaccharide structures. In: Chang JY, Lewis AJ, eds. Pharmacological Methods in the Control of Inflammation. New York: Alan R. Liss, 1989:381-94
182. Cromartie WJ, Craddock JG, Schwab JH, Anderle SK, Yang CH. Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med 1977; 146: 1585-602
183. Stimpson SA, Brown RR, Anderle SK et al. Arthropathic properties of cell wall polymers from normal flora bacteria. Infect Immun 1986; 51: 240-9
184. Severijnen AJ, Hazenberg MP, Van De Murwe JP. Induction of chronic arthritis in rats by cell wall fragments of anaerobic coccoid rods isolated from the faecal flora of patients with crohn's disease. Digestion 1988; 39: 118-25
185. Zhang X, Rimpilainen M, Simelyte E, Toivanen P. What determines arthritogenicity of bacterial cell wall? A study on Eubacterium cell wall-induced arthritis. Rheumatology (Oxf.) 2000; 39: 274-82
186. Yoshino S, Sasatomi E, Mori Y, Sagai M. Oral administration of lipopolysaccharide exacerbates collagen-induced arthritis in mice. J Immunol 1999; 163: 3417-22
187. Lichtman SN, Bachmann S, Munoz SR et al. Bacterial cell wall polymers (peptidoglycan-polysaccharide) cause reactivation of arthritis. Infect Immun 1993; 61: 4645-53
188. Stoughton RB. Enzymatic cytolysis of epithelium by filtrates from patients with ulcerative colitis. Invest Dermatol 1953; 20: 353-6
189. Cromartie WJ, Anderle SK, Schwab JH, Dalldorf FG. Experimental arthritis, carditis and pinnitis induced by systemic injection of group A streptococcal cell walls into guinea pigs. In: Parker MT, ed. Proceedings of the Ninth International Symposium on Streptococci and Streptococcal diseases, Windsor: Reedbooks, 1978: 50-2
190. Ohanian SH, Schwab JH. Persistence of group A streptococcal cell walls related to chronic inflammation of rabbit dermal connective tissue. J Exp Med 1967; 125: 1137-48
191. Rosebaum JT, McDevitt HO, Guss RB, Egbert PR. Endotoxin induced uveitis in rats as a model for human disease. Nature 1980; 286: 611-13
192. Wells A, Pararajasegaram G, Baldwin M, Yang CH, Hammer M, Fox A. Uveitis and arthritis induced by systemic injection of streptococcal cell walls. Invest Ophthalmol Vis Sci(PA) 1986;27:921-5
193. Merino G, Fujino Y, Hanashiro RK. Lipoteichoic acid as an inducer of acute uveitis in the rat. Invest Ophthalmol Vis Sci 1998; 39: 1251-6
194. Waksman BH, Bullington SJ Studies of arthritis and other lesions induced in rats by ingestion of mycobacterial adjuvant. Arch Ophthalmol 1960; 64: 751-61
195. Baggia S, Lyons JL, Angell E et al. A novel model of bacterially-induced acute anterior uveitis in rats and the lack of effect from HLA-B27 expression. J Invest Med 1997;45:295-301
196. Shen DF, Chang MA, Matteson DM, Buggage R, Kozhich AT, Chan CC. Biphasic ocular inflammatory response to endotoxin-induced uveitis in the mouse. Arch Ophthalmol 2000; 118:521-7
197. Sartor RB, Anderle SK, Rifai N, Goo DA, Cromartie WJ, Schwab JH. Protracted anemia associated with chronic, relapsing systemic inflammation induced by arthropathic peptidoglycan-polysaccharide polymers in rats. Infect Immun 1989; 57: 1177-85
198. Sartor RB. Pathogenetic and clinical relevance of cytokines in inflammatory bowel disease. Immunol Res 1991; 10: 465-71
199. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor a in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-17
200. Tracey KJ, Wei H, Manogue KR. Cachectin tumor necrosis factor induces cachexia, anemia and inflammation. J Exp Med 1988; 167: 1211-27
201. Otterness IG, Golden HW, Brissette WH, Saymour PA, Daumy GO. Effects of continuously administered murine interleukin la: Tolerance development and granuloma formation. Infect Immun 1989; 57: 2742-50
202. Lichtman SN, Wang J, Reinstein JL, Lemasters JJ Role of TNFa in causing hepatobiliary injury in rats with experimental small bowel bacterial overgrowth. In: Knook DL, Wisse E, eds. Cefls of the Hepatic Sinusoid. Leiden: Kupffer Cefl Foundation, 1993: 141-2
203. Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 2338-42
204. Kaminski DL. Arachidonic acid metaboHtes in hepatobiUary physiology and disease. Gastroenterology 1989; 97: 781-92
205. Wahl SM. Cellular and molecular interactions in the induction of inflammation in rheumatic diseases. In: Kresina TF, ed. Monoclonal Antibodies, Cytokines, and Arthritis. New York: Marcel Dekker, 1991
206. Schattner A, Kozak N, Lassry Y, Sokolovskaya N. Primary intestinal T-cell lymphoma and sclerosing cholangitis: A cytokine-mediated association? J Intern Med 1998; 244: 537-41
207. Broome U, Hultcrantz R, Lefvert AK, Yi Q. Cytokine production from colonic T cefls in patients with ulcerative colitis with and without primary sclerosing cholangitis. Dis Colon Rectum 1998; 41: 1543-9
208. Sutherland LR, Martin F, Bailey RJ et al. A randomized, placebo-controUed, double-blind trial of mesalamine in the maintenance of remission of crohn's disease. The Canadian Mesalamine for Remission of crohn's Disease Study Group. Gastroenterology 1997; 112: 1069-77
209. Bansal AS, Thomson A, Steadman C et al. Serum levels of interleukins 8 and 10, interferon gamma, granulocytemacrophage colony stimulating factor and soluble CD23 in patients with primary sclerosing cholangitis. Autoimmunity 1997; 26: 223-9
210. Stimpson SA, Dalldorf FG, Otterness IG, Schwab JH. Exacerbation of arthritis by IL-1 in rat joints previously injured by peptidoglycan- polysaccharide. J Immunol 1988; 140:2964-9
211. Stimpson SA, Dafldorf FG, Otterness IG, Schwab JH. Pain and reactivation of arthritis induced by recombinant cytokines in rat ankles previously injured by peptidoglycan polysaccharide. Arthritis Rheum 1988; 31: S49
212. Brandes ME, Allen JB, Ogawa H, Wahl SM. Transforming growth factor bl suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991; 87: 1108-13
213. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-Alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481-8
214. Schulte CM, Dignass AU, Goebell H, Roher HD, Schulte KM. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2000; 119: 909-20
215. Tatakis DN, Guglielmoni P. HLA-B27 transgenic rats are susceptible to accelerated alveolar bone loss. J Periodontol. 2000; 71: 1395-400
216. Mano Y, Ishii M, Okamoto H, Igarashi T, Kobayashi K, Toyota T. Effect of tumor necrosis factor alpha on intrahepatic bile duct epithelial cell of rat liver. Hepatology 1996; 23: 1602-7
217. Strazzabosco M, SpirH C, Okohcsanyi L. Pathophysiology of the intrahepatic biliary epithelium. J Gastroenterol Hepatol 2000; 2000; 15: 244-53
218. Reynoso-Paz S, Coppel RL, Mackay IR, Bass NM, Ansari AA, Gershwin ME. The immunobiology of bile and biliary epithelium. Hepatology 1999; 30: 351-7
219. Ponsioen CY, Kuiper H, Ten Kate FJ, van Milhgen d, van Deventer SJ, Tytgat GN. Immunohistochemical analysis of inflammation in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 1999; 11: 769-74
220. Tjandra K, Sharkey KA, Swain MG. Progressive development of Thl-Type hepatic cytokine profile in rats with experimental cholangitis. Hepatology 2000; 31: 280-90
221. Berg PA, Klein R, Rocken M. Cytokines in primary biliary cirrhosis. Semin Liver Dis 1997; 17: 115-23
222. Broome U, Hultcrantz R, Scheynius A. Lack of concomitant expression of ICAM-1 and HLA-DR on bile duct cells from patients with primary sclerosing cholangitis and pri mary biliary cirrhosis. Scand J Gastroenterol 1993; 28: 126-30
223. Himeno H, Saibara T, Onishi S, Yamamoto Y, Enzan H. Administration of interleukin-2 induces major histocompatibility complex class II expression on the biliary epithelial cells, possibly through endogenous interferon-gamma production. Hepatology 1992; 16: 409-17
224. Ayres RC, Neuberger JM, Shaw J, Joplin R, Adams DH. Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: Effect of pro-inflammatory cytokines. Gut 1993; 34: 1245-9
225. Cruickshank SM, Southgate J, Selby PJ, Trejdosiewicz LK. Expression and cytokine regulation of immune recognition elements by normal human biliary epithelial and established liver cell lines in vitro. J Hepatol 1998; 29: 550-8
226. Leon MP, Bassendine MF, Gibbs P, Thick M, Kirby JA. Immunogenicity of biliary epithelium: Study of the adhesive interaction with lymphocytes. Gastroenterology 1997; 112: 968-77
227. Cruickshank SM, Southgate J, Selby PJ, Trejdosiewicz LK. Inhibition of T cell activation by normal human biliary epithelial cells. J Hepatol 1999; 31: 1026-33
228. Jung HC, Eckmann L, Yang SK et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest 1995; 95: 55-65
229. Jobin C, Sartor RB. The I kappa B/NF-kappa B system: A key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 2000; 278: C451-62
230. Smccts TJ, Dolhain RJ, Breedveld EC, Tak PR Analysis of the cellular inflltratcs and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. J Pathol 1998; 186: 75-81
231. Palombella VJ, Conner EM, Fusclcr JW et al. Role of the protcasomc and NF-kappaB in streptococcal cell wallinduced polyarthritis. Proc Natl Acad Sci USA 1998; 95: 15671-6
232. McCall RD, Haskill S, Zimmermann EM, Lund PK, Thompson RC, Sartor RB. Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology 1994; 106: 960-72
233. Hcrfarth HH, Bocker U, Janardhanam R, Sartor RB. Subtherapeutic corticosteroids potentiate the ability of interleukin 10 to prevent chronic inflammation in rats. Gastroenterology 1998; 115: 856-65
234. Stadnicki A, Sartor RB, Janardham R et al. Specific inhibition of plasma kallikrein modulates chronic granulomatous intestinal and systemic inflammation in genetically susceptible rats. FASEB J 1998; 12: 325-33
235. Yocum DE, Allen JB, Wahl SM, Calandra GB, Wilder RL. Inhibition by cyclosporin A of streptococcal cell wallinduced arthritis and hepatic granulomas in rats. Arthritis Rheum 1986;29:262-73
236. Van Den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. crohn's disease associated with spondyloarthropathy: Effect of TNF-Alpha blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821-2
237. Taurog JD, Maika SD, Satumtira N et al. Inflammatory disease in HLA-B27 transgenic rats. Immunol Rev 1999; 169:209-23
238. Morteau O, Morham SG, Sellon R et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest 2000; 105: 469-78
239. Salmi M, Rajala P, Jalkanen S. Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocyte-subtype specific adhesion. J Clin Invest 1997;99:2165-72
240. Wahl SM, Hunt DA, Allen JB, Wilder RL, Paglia L, Hand AR. Bacterial cell wall-induced hepatic granulomas. An in vivo model of T cell-Dependent fibrosis. J Exp Med 1986; 163: 884-902
241. Breban M, Fernandez-Sueiro JL, Richardson JA et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol 1996; 156: 794-803
242. Ohta K, Yamagami S, Taylor AW, Streilein JW. IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 2000; 41: 2591-9
243. Marie O, Thillaye-Goldenberg B, Naud MC, de Kozak Y. Inhibition of endotoxin-induced uveitis and potentiation of local TNF-Alpha and interleukin-6 mRNA expression by interleukin-13. Invest Ophthalmol Vis Sci 1999; 40: 2275-82
244. Llorente L, Richaud-Patin Y, Alvarado C, Reyes E, Alcocer-Varela J, Orozco-Topete R. Elevated Thl cytokine mRNA in skin biopsies and peripheral circulation in patients with erythema nodosum. Eur Cytokine Netw 1997; 8: 67-71
245. Moraes MO, Sarno EN, Teles RM et al. Anti-inflammatory drugs block cytokine mRNA accumulation in the skin and improve the clinical condition of reactional leprosy patients. J Invest Dermatol 2000; 115: 935-41
246. Sternberg EM, Hill JM, Chrousos GP et al. Inflammatory mediator-induced hypothalamic pituitary adrenal axis activation is defective in streptococcal cell wall arthritissusceptible Lewis rats. Proc Natl Acad Sci USA 1989; 86: 2374-8
247. Bristol LA, Durum SK, Eisenberg SP. Differential regulation of group A streptococcal pcptidoglycan-polysaccharidc (PG-APS)-slimulated macrophage production of IL-1 by rat strains susceptible and resistant to PG-APS-induced arthritis. Cell Immunol 1993; 149: 130-43
248. Skaleric U, Allen JB, Mcrgenhagen SE, Wahl SM. Inhibitors of reactive oxygen intermediates suppress bacterial cell wall induced arthritis. J Immunol 1991; 147: 2559-64
249. McCall RD, Haskill JS, Sartor RB. Interleukin 1 and IL 1 receptor antagonist gene expression correlate with activity of inflammation in spontaneously relapsing enterocolitis in rats. Gastroenterology 1991; 100: 766A (abstract
250. Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-95
251. Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995; 154:2434-40
252. Stokkers PC, van Aken BE, Basoski N, Reitsma PH, Tytgat GN, Van Deventer SJ Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease. Gut 1998; 43: 33-9
253. LohmuUer JL, Pemberton JH, Dozois RR, Ilstrup D, van Heerden J Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-Anal anastomosis. Ann Surg 1990; 211: 662-7
254. Salemans JM, Nagengast FM, Lubbers EJ, Kuijpers JH. Postoperative and long-Term results of ileal pouch-Anal anastomosis for ulcerative colitis and familial polyposis coli. DigDisSci 1992; 37: 1882-9
255. Helwig U, RizzeUo F, Cifone G et al. Elevated IL-10 levels in pouch-Tissue after probiotic therapy. Immunol Lett 1999; 69: 159 (abstract
256. Gionchetti P, Rizzello F, Venturi A et al. Maintenance treatment of chronic pouchitis: A randomized placebo-con trolled, double-blind trial with a new probiotic preparation. Gastroenterology 1998; 114: A985 (abstract
257. Penna C, Dozois R, Tremaine W et al Pouchitis after ileal pouch-Anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38: 234-9
258. Chapman RW. Role of immune factors in the pathogenesis of primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 1-4
259. Sartor RB, Green KD, Anderle SK. Spontaneously reactivating granulomatous enterocolitis with extraintestinal inflammation induced by bacterial cell wall polymers in genetically susceptible rats. Gastroenterology 1989; 96: 442A (abstract
260. Braun J, Yin Z, Spiller I et al. Low secretion of tumor necrosis factor alpha, but no other Thl or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum 1999; 42: 2039-44
261. Schoppet M, Bubert A, Huppertz HL Dendritic cell function is perturbed by Yersinia enterocolitica infection in vitro. Clin Exp Immunol 2000; 122: 316-23
262. MacDonald TT, Pettersson S. Bacterial regulation of intestinal immune responses. Inflam Bowel Dis 2000; 6: 116-22
263. Nickerson CL, Lutha HS, David CS. Role of enterobacteria and HLA B27 in spondyloarthropathies: Studies with transgenic mice. Ann Rheum Dis 1990; 49: 426-33
264. Falgarone G, Blanchard HS, Riot B, Simonet M, Breban M. Cytotoxic T-cell-mediated response against Yersinia pseudotuberculosis in HLA-B27 transgenic rat. Infect Immun 1999; 67: 3773-9
265. Stagg A J, Breban M, Hammer RE, Knight SC, Taurog JD. Defective dendritic cell (DC) function in a HLA-B27 transgenic rat model of spondyloarthropathy (SpA). Adv Exp Med Biol 1995; 378: 557-9
266. Kingsbury DJ, Mear JP, Witte DP, Taurog JD, Roopenian DC, Colbert RA. Development of spontaneous arthritis in beta2-microglobulin-Deficient mice without expression of HLA-B27: Association with deficiency of endogenous major histocompatibility complex class I expression. Arthritis Rheum 2000; 43: 2290-6
267. Leirisalo-Repo M, Lauhio A, Repo H. Chemotaxis and chemiluminescence responses of synovial fluid polymorphonuclear leucocytes during acute reactive arthritis. Ann Rheum Dis 1990; 49: 615-19
268. Leirisalo-Repo M. Inflammation in HLA B27 associated diseases. Scand J Rheumatol Suppl. 1990; 87: 140-7
269. Tonkonogy SL, Hoentjen F, Sprengers D, Goerres M, Sartor RB, Dieleman LA. Altered profile of the immunoregulatory cytokines IL-10, IL-12 and IFN-gamma in HLA B27 transgenic rat mesenteric lymph node cells stimulated with cecal bacterial components. FASEB J 2001; 15: A372 (abstract
270. Powell FC, Schroeter AL, Su WPD, Perry HO. Pyoderma gangrenosum: A review of 86 patients. J Q Med 1985; 217: 173-86
271. Mitchell SA, Chapman RW. Primary sclerosing cholangitis. Clin Rev Allergy Immunol 2000; 28: 185-214
272. Spurkland A, Saarinen S, Boberg KM et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Ant 1999; 53: 459-69
273. Bernal W, Moloney M, Underbill J, Donaldson PT. Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis. J Hepatol 1999; 30: 237-1
274. Donaldson PT, Norris S, Constantini PK, Bernal W, Harrison P, Williams R. The interleukin-1 and interleukin-10 gene polymorphisms in primary sclerosing cholangitis: No associations with disease susceptibility/resistance. J Hepatol 2000; 32: 882-6
275. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: An animal model of HLA-B27-Associated human disorders. Cell 1990; 63: 1099-112
276. Krug HE, Taurog JD. HLA-B27 has no elfect on the phenotypic expression of progressive ankylosis in ank/ank mice. J Rheumatol 2000; 27: 1257-9
277. Alvarez I, Lopez dCJ HLA-B27 and immunogenetics of spondyloarthropathies. Curr Opin Rheumatol 2000; 12: 248-53
278. Lopez dCJ The pathogenetic role of HLA-B27 in chronic arthritis. Curr Opin Immunol 1998; 10: 59-66
279. Edwards JC, Bowness P, Archer Jr. Jekyll and Hyde: The transformation of HLA-B27. Immunol Today 2000; 21: 256-60
280. Weiss EH, Schliesser G, Botteron C et al. HLA class I transgenic mice as model system to study MHC restricted antigen recognition in man. Scand J Rheumatol 1990; 87: 91-6
281. Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill GJ, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000; 118: 274-8
282. de la Concha EG, Fernandez-Arquero M, Lopez-Nava G et al. Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL. Gastroenterology 2000; 119: 1491-5
283. Yeon HB, Lindor NM, Seidman JG, Seidman CE. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q. Am J Hum Genet 2000; 66: 1443-8
284. van Hoogstraten HJ, Wolfhagen FH, Van De Meeberg PC et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: Results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 1998; 29: 417-23
285. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988; 95: 1036-2
286. Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol 1997; 36: 1089-94
287. Adibi SA, Stanko RT. Perspectives on gastrointestinal surgery for treatment of morbid obesity: The lesson learned. Gastroenterology 1984; 87: 1381-91